Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic target for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon output. GLP-1 agents possess promising therapeutic efficacy in treating type 2 dia